Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting
eLife · 04.12.2023 · 12
DOI: 10.7554/elife.86189 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 04.12.2023. Verfasst von Ian R Outhwaite und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacological Sciences, Stony Brook University, Stony Brook, United States. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Damon Runyon Cancer Research Foundation, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. However, the high sequence and structural conservation of the catalytic kinase domain complicate the development of selective kinase inhibitors. Inhibition of off-target kinases makes it difficult to study the mechanism of inhibitors in biological systems. Current efforts focus on the development of inhibitors with improved selectivity. Here, we present an alternative solution to this problem by combining inhibitors with divergent off-target effects. We develop a multicompound–multitarget scoring (MMS) method that combines inhibitors to maximize target inhibition and to minimize off-target inhibition. Additionally, this framework enables optimization of inhibitor combinations for multiple on-targets. Using MMS with published kinase inhibitor datasets we determine potent inhibitor combinations for target kinases with better selectivity than the most selective single inhibitor and validate the predicted effect and selectivity of inhibitor combinations using in vitro and in cellulo techniques. MMS greatly enhances selectivity in rational multitargeting applications. The MMS framework is generalizable to other non-kinase biological targets where compound selectivity is a challenge and diverse compound libraries are available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacological Sciences, Stony Brook University, Stony Brook, United States.
- Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, United States.
- Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt am Main, Germany.
- Structural Genomics Consortium, Buchmann Institute for Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
ORCID-Profile: Ian R Outhwaite, Sukrit Singh, Stefan Knapp, John D Chodera, Markus A Seeliger
Förderung
- Damon Runyon Cancer Research Foundation
- NIGMS NIH HHS
- NIH HHS
- NCI NIH HHS
- Wellcome Trust
- National Institutes of Health
- Structural Genomics Consortium
- German Translational Cancer Network
Zitieren
APA
Outhwaite, I. R., Singh, S., Berger, B. T., Knapp, S., Chodera, J. D., & Seeliger, M. A. (2023). Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting. eLife, 12. https://doi.org/10.7554/elife.86189
Vancouver
Outhwaite IR, Singh S, Berger BT, Knapp S, Chodera JD, Seeliger MA. Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting. eLife. 2023;12. doi:10.7554/elife.86189
BibTeX
@article{Outhwaite2023,
author = {Outhwaite, Ian R and Singh, Sukrit and Berger, Benedict-Tilman and Knapp, Stefan and Chodera, John D and Seeliger, Markus A},
title = {Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.86189}
}
EUVIMED